Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Nature Medicine

Volumn 10, Issue 9, 2004, Pages 942-949

  Curiel, Tyler J ^a   Coukos, George ^b   Zou, Linhua ^a   Alvarez, Xavier ^a   Cheng, Pui ^a   Mottram, Peter ^a   Evdemon Hogan, Melina ^a   Conejo Garcia, Jose R ^b   Zhang, Lin ^b   Burow, Matthew ^a   Zhu, Yun ^a   Wei, Shuang ^a   Kryczek, Ilona ^a   Daniel, Ben ^a   Gordon, Alan ^c   Myers, Leann ^a   Lackner, Andrew ^a   Disis, Mary L ^d   Knutson, Keith L ^d   Chen, Lieping ^e   Zou, Weiping ^a   more..

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL22 CHEMOKINE; CD4 ANTIGEN; CHEMOKINE; INTERLEUKIN 2 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; LYMPHOCYTE MIGRATION; MACROPHAGE ACTIVATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ASCITES; CD4-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CHEMOKINES, CC; DENDRITIC CELLS; DNA-BINDING PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MICE; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 4644237613     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1093     Document Type: Article

References (48)

1. Romero, P. et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188, 1641-1650 (1998).
2. Lee, P.P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685 (1999).
3. + lymphocytes as compared with nonprofessional APC. J. Immunol. 167, 1188-1197 (2001).
4. Dunbar, R.R. et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol. 165, 6644-6652 (2000).
5. Curiel, T.J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated anti-tumor immunity. Nat. Med. 9, 562-567 (2003).
6. Yee, C., Riddell. S.R. & Greenberg, P.D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9, 702-708 (1997).
7. Maio, M. & Parmiani, G. Melanoma immunotherapy: new dreams or solid hopes? Immunol. Today 17, 405-407 (1996).
8. Maeurer, M.J., Storkus, W.J., Kirkwood, J.M. & Lotze, M.T. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res. 6, 11-24 (1996).
9. Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003).
10. Pardoll, D. T cells and tumours. Nature 411, 1010-1012 (2001).
11. Schreiber, H., Wu, T.H., Nachman, J. & Kast, W.M. Immunodominance and tumor escape. Semin. Cancer Biol. 12, 25-31 (2002).
12. Munn, D.H. et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870 (2002).
13. Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. Immunol. 3, 999-1005 (2002).
14. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400 (2002).
15. Wood, K.J. & Sakaguchi, S. Regulatory lymphocytes: regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3, 199-210 (2003).
16. Von Herrath, M.G. & Harrison, L.C. Regulatory lymphocytes: antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. 3, 223-232 (2003).
17. Bach, J.F. Regulatory lymphocytes: regulatory T cells under scrutiny. Nat. Rev. Immunol. 3, 189-198 (2003).
18. + regulatory T cells. Curr. Opin. Immunol. 13, 644-649 (2001).
19. + T cells with regulatory properties from human blood. J. Exp. Med. 193, 1303-1310 (2001).
20. + cells: a naturally occurring population of regulatory T cells. Blood 98, 2736-2744 (2001).
21. + T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193, 1295-1302 (2001).
22. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-4772 (2001).
23. Woo, E.Y. et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J. Immunol. 168, 4272-4276 (2002).
24. Liyanage, U.K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
25. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
26. + regulatory T cells. Nat. Immunol. 4, 330-336 (2003).
27. + T regulatory cells. Nat. Immunol. 4, 337-342 (2003).
28. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance, Immunol. Rev. 182, 18-32 (2001).
29. hi regulatory cells in human peripheral blood. J. Immunol. 167, 1245-1253 (2001).
30. Zou, W. et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7, 1339-1346 (2001).
31. Knutson, K.L., Schiffman, K. & Disis. M.L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. invest. 107, 477-484 (2001).
32. hi regulatory T cell function. J. Immunol. 169, 6210-6217 (2002).
33. Markman, M. Optimizing primary chemotherapy in ovarian cancer. Hematol. Oncol. Clin. North Am. 17, 957-968, viii (2003).
34. Shevach, E.M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18, 423-449 (2000).
35. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193, 1311-1318 (2001).
36. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
37. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211-5218 (1999).
38. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61, 8643-8646 (2001).
39. + immunoregulatory cells. J. Immunol. 167, 1137-1140 (2001).
40. + T cell-mediated graft rejection: implications for anti-CD154 immunotherapy. J. Immunol. 169, 5401-5404 (2002).
41. + regulatory T cells. J. Exp. Med. 194, 847-853 (2001).
42. Wu, M., Fang, H. & Hwang, S.T. Cutting edge: CCR4 mediates antigen-primed T cell binding to activated dendritic cells. J. Immunol. 167, 4791-4795 (2001).
43. Tang, H.L. & Cyster, J.G. Chemokine Up-regulation and activated T cell attraction by maturing dendritic cells. Science 284, 819-822 (1999).
44. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
45. Bieche, I. et al. Quantification of estrogen receptor α and β expression in sporadic breast cancer. Oncogene 20, 8109-8115 (2001).
46. Zou, W. et al. Quantification of cytokine gene expression by competitive PCR using a colorimetric assay. Eur. Cytokine Netw. 6, 257-264 (1995).
47. Zou, W. et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by β-chemokines rather than IL-12. J. Immunol. 165, 4388-4395 (2000).
48. Lecoeur, H., Fevrier, M., Garcia, S., Riviere, Y. & Gougeon, M.L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods 253, 177-187 (2001).